GLP-1s are linked to a broad range of adverse events — largely gastrointestinal, metabolic, and psychological — across ...

GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 ...

Adults with type 2 diabetes and overweight or obesity who use a GLP-1 receptor agonist have similar risk for kidney cancer as ...

The burden of T2DM is increasing worldwide, with enormous implications for morbidity and mortality. Early and effective ...

Introduction India’s T2D population carries a substantial burden-nearly two-thirds of individuals with T2D are overweight or obese, indicating a significant cardio-metabolic risk burden (1).

GLP-1 receptor agonists were associated with reduced risk of alcohol, cannabis, cocaine, nicotine and opioid use disorders, as well as other substance use disorders, suggesting potential prevention ...

In patients with type 2 diabetes and cirrhosis, SGLT2 inhibitors show increased efficacy over DPP-4 inhibitors in kidney, ...

New data reveal key differences in antihyperglycaemic agents safety for older adults with Type 2 diabetes. Learn more.

Hua Medicine Announces 2025 Annual Results. Hua Medicine Announces 2025 Annual Results - Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching ...

Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...

Type 2 diabetes is one of the most common long-term health conditions in the world. It affects millions of people and ...

Weight-loss injections that have become famous for helping people shed pounds may also help some patients with advanced cancer live longer when the disease has spread to the brain, according to a new ...